Tvardi Therapeutics Inc (TVRD) Stock Price, Quote & News

Company Profile

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 489 8654

Website: tvarditherapeutics.com

Address:

3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States

Kplt1972 Jul. 28 at 4:51 PM

$TVRD get out while you can

0 · Reply

graniterock Jul. 23 at 6:17 PM

$TVRD I've just started buying some of this waiting for the results of phase 2 ,no doubt the upgrades are in lieu of great results whenever they may be posted. Does anyone follow this closely and when might we expect some words from the company thx

0 · Reply

Kplt1972 Jul. 23 at 3:49 PM

$TVRD zero

0 · Reply

Etiqute Jul. 23 at 12:36 PM

$TVRD Key Pipeline Catalysts (2026) TTI-109 Progression: Following positive Phase 1 tolerability data in July, Tvardi plans to advance this oral STAT3 inhibitor into clinical trials for dermatologic and gastrointestinal diseases. [1] TTI-101 Data: Topline data from the Phase 1b/2 trial of TTI-101 targeting hepatocellular carcinoma (liver cancer) is on track to release in the second half of 2026. [1, 2] Cash Runway: The company reports $25 million in cash as of its last audit, which it expects will fund operations through these crucial clinical readouts into Q4 2026. [1]

0 · Reply

Etiqute Jul. 23 at 12:36 PM

$TVRD Analyst Ratings and Price Targets Consensus Rating: Balanced at a Moderate Buy across major firms. Average Price Target: Settles around $19.67, though recent targets after the trial data sit closer to $10.00. Recent Upgrades: Piper Sandler upgraded the stock to Overweight, and Raymond James set a $10 price target. [1, 2, 3]

1 · Reply

Etiqute Jul. 23 at 12:35 PM

$TVRD 7 sites Tvardi Therapeutics (TVRD) stock is trading around $2.70 following positive Phase 1 clinical trial results for its drug TTI-109, an upgraded analyst rating, and upcoming second-quarter earnings. Yahoo Finance +3 Recent Clinical and Financial Updates Phase 1 Trial Success: Reported positive Phase 1 results for TTI-109 (an oral STAT3 inhibitor for inflammatory diseases) showing improved tolerability. Analyst Action: Raymond James upgraded the stock to an Outperform rating with a $10 price target. Upcoming Earnings: Q2 2026 financial results are expected around August 13, 2026. Prior Volatility: The stock previously faced heavy losses in late 2025 after a Phase 2 fibrosis study missed primary goals.

0 · Reply

Kplt1972 Jul. 20 at 11:39 PM

$TVRD salvage some pennies now before it goes to zero

0 · Reply

Kplt1972 Jul. 20 at 1:44 PM

$TVRD zero soon

0 · Reply